Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat

European Journal of Pharmacology

Volumn 637, Issue 1-3, 2010, Pages 70-76

  Liu, Wei Jing ^a   Jin, Heung Yong ^a   Park, Ji Hyun ^a   Baek, Hong Sun ^a   Park, Tae Sun ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Diabetic peripheral neuropathy; Micro macroangiopathy; Neuro inflammation; Rimonabant

Indexed keywords

GLUCOSE; PLACEBO; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFICACY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SKIN BLOOD FLOW; SKIN CAPILLARY; SKIN NERVE; SPINAL CORD; STIMULUS RESPONSE; STREPTOZOCIN DIABETES; TISSUE LEVEL; TREADMILL EXERCISE; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NEURONS; PERIPHERAL NERVES; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SKIN; STREPTOZOCIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953292892     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.004     Document Type: Article

References (50)

1. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997, 132:104-106.
2. Beiswenger K.K., Calcutt N.A., Mizisin A.P. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem. 2008, 110:351-362.
3. Bianchi R., Buyukakilli B., Brines M., Savino C., Cavaletti G., Oggioni N., Lauria G., Borgna M., Lombardi R., Cimen B., Comelekoglu U., Kanik A., Tataroglu C., Cerami A., Ghezzi P. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:823-828.
4. Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
5. Chen Y.S., Chung S.S., Chung S.K. Noninvasive monitoring of diabetes-induced cutaneous nerve fiber loss and hypoalgesia in thy1-YFP transgenic mice. Diabetes 2005, 54:3112-3118.
6. Costa B., Trovato A.E., Colleoni M., Giagnoni G., Zarini E., Croci T. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 2005, 116:52-61.
7. Croci T., Zarini E. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br. J. Pharmacol. 2007, 150:559-566.
8. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005, 353:2121-2134.
9. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008, 51:1356-1367.
10. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat. Rev. Drug Discov. 2008, 7:438-455.
11. Di Marzo V., Szallasi A. Rimonabant in rats with a metabolic syndrome: good news after the depression. Br. J. Pharmacol. 2008, 154:915-917.
12. Dol-Gleizes F., Paumelle R., Visentin V., Mares A.M., Desitter P., Hennuyer N., Gilde A., Staels B., Schaeffer P., Bono F. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29:12-18.
13. Edwards J.L., Vincent A.M., Cheng H.T., Feldman E.L. Diabetic neuropathy: mechanisms to management. Pharmacol. Ther. 2008, 120:1-34.
14. Ellington H.C., Cotter M.A., Cameron N.E., Ross R.A. The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology 2002, 42:966-975.
15. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., Pacher P., Harvey-White J., Luft F.C., Sharma A.M., Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
16. Flynn M.D., Tooke J.E. Diabetic neuropathy and the microcirculation. Diabet. Med. 1995, 12:298-301.
17. George A., Schmidt C., Weishaupt A., Toyka K.V., Sommer C. Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. Exp. Neurol. 1999, 160:124-132.
18. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am. J. Med. 2007, 120:S18-S28. discussion S29-32.
19. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54:161-202.
20. Hoybergs Y.M., Biermans R.L., Meert T.F. The impact of bodyweight and body condition on behavioral testing for painful diabetic neuropathy in the streptozotocin rat model. Neurosci. Lett. 2008, 436:13-18.
21. Ionescu-Tirgoviste C., Pruna S., Bajenaru O., Cheta D., Mincu I. The perception threshold to an electric stimulus deeply applied in the lower limbs in normal and diabetic subjects. Diabetes Res. Clin. Pract. 1987, 3:249-256.
22. Jamshidi N., Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 2001, 134:1151-1154.
23. Jin H., Piao M., Park J., Baek H., Lee S., Kim W., Park S., Kim C., Koh G., Park T. Effect of cartilage oligomeric matrix ProteinAngiopoietin-1 on peripheral nerves in db/db diabetic mice. Curr. Ther. Res. 2008, 69:343-355.
24. Karvestedt L., Martensson E., Grill V., Elofsson S., von Wendt G., Hamsten A., Brismar K. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 2009, 32:317-322.
25. Kim S.R., Chung Y.C., Chung E.S., Park K.W., Won S.Y., Bok E., Park E.S., Jin B.K. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity. Mol. Neurobiol. 2007, 35:245-254.
26. Kiso T., Nagakura Y., Toya T., Matsumoto N., Tamura S., Ito H., Okada M., Yamaguchi T. Neurometer measurement of current stimulus threshold in rats. J. Pharmacol. Exp. Ther. 2001, 297:352-356.
27. Kon Y., Endoh D., Iwanaga T. Expression of protein gene product 9.5, a neuronal ubiquitin C-terminal hydrolase, and its developing change in sertoli cells of mouse testis. Mol. Reprod. Dev. 1999, 54:333-341.
28. Lauria G., Lombardi R., Borgna M., Penza P., Bianchi R., Savino C., Canta A., Nicolini G., Marmiroli P., Cavaletti G. Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J. Peripher. Nerv. Syst. 2005, 10:202-208.
29. Massa F., Monory K. Endocannabinoids and the gastrointestinal tract. J. Endocrinol. Investig. 2006, 29:47-57.
30. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91:3171-3180.
31. McGaraughty S., Chu K.L., Dart M.J., Yao B.B., Meyer M.D. A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors. Neuroscience 2009, 158:1652-1661.
32. Muthian S., Rademacher D.J., Roelke C.T., Gross G.J., Hillard C.J. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 2004, 129:743-750.
33. Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?. Arterioscler. Thromb. Vasc. Biol. 2009, 29:7-9.
34. Pasquariello N., Catanzaro G., Marzano V., Amadio D., Barcaroli D., Oddi S., Federici G., Urbani A., Finazzi Agro A., Maccarrone M. Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. J. Biol. Chem. 2009, 284:29413-29426.
35. Pegorini S., Zani A., Braida D., Guerini-Rocco C., Sala M. Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br. J. Pharmacol. 2006, 147:552-559.
36. Pellegrini-Giampietro D.E., Mannaioni G., Bagetta G. Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. FEBS J. 2009, 276:2-12.
37. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
38. Qiang X., Satoh J., Sagara M., Fukuzawa M., Masuda T., Sakata Y., Muto G., Muto Y., Takahashi K., Toyota T. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia 1998, 41:1321-1326.
39. Saez-Cassanelli J.L., Fontanella G.H., Delgado-Garcia J.M., Carrion A.M. Functional blockage of the cannabinoid receptor type 1 evokes a kappa-opiate-dependent analgesia. J. Neurochem. 2007, (Electronic publication ahead of print).
40. Satoh J., Yagihashi S., Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp. Diabesity Res. 2003, 4:65-71.
41. Schafer A., Pfrang J., Neumuller J., Fiedler S., Ertl G., Bauersachs J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br. J. Pharmacol. 2008, 154:1047-1054.
42. Scheen A.J., Paquot N. Inhibitors of cannabinoid receptors and glucose metabolism. Curr. Opin. Clin. Nutr. Metabol. Care. 2008, 11:505-511.
43. Shen M., Thayer S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 1998, 54:459-462.
44. Sommer C., Schomacher M., Berger C., Kuhnert K., Muller H.D., Schwab S., Schabitz W.R. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol. 2006, 112:277-286.
45. Takekuma K., Ando F., Niino N., Shimokata H. Prevalence of hyperesthesia detected by current perception threshold test in subjects with glucose metabolic impairments in a community. Intern. Med. 2002, 41:1124-1129.
46. Vickers S.P., Webster L.J., Wyatt A., Dourish C.T., Kennett G.A. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003, 167:103-111.
47. Zassler B., Weis C., Humpel C. Tumor necrosis factor-alpha triggers cell death of sensitized potassium chloride-stimulated cholinergic neurons. Brain Res. Mol. Brain Res. 2003, 113:78-85.
48. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. NeuroSci. 2003, 17:2750-2754.
49. Zhang M., Martin B.R., Adler M.W., Razdan R.K., Ganea D., Tuma R.F. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 2008, 152:753-760.
50. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come?. Diabetes Care 2008, 31(Suppl 2):S255-S261.